PL1824504T3 - Kombinacja przeciwnowotworowa zawierająca vegf-trap i 5fu lub jedną z jego pochodnych - Google Patents

Kombinacja przeciwnowotworowa zawierająca vegf-trap i 5fu lub jedną z jego pochodnych

Info

Publication number
PL1824504T3
PL1824504T3 PL05824581T PL05824581T PL1824504T3 PL 1824504 T3 PL1824504 T3 PL 1824504T3 PL 05824581 T PL05824581 T PL 05824581T PL 05824581 T PL05824581 T PL 05824581T PL 1824504 T3 PL1824504 T3 PL 1824504T3
Authority
PL
Poland
Prior art keywords
trap
derivatives
combinations containing
containing vegf
antitumor combinations
Prior art date
Application number
PL05824581T
Other languages
English (en)
Polish (pl)
Inventor
Patricia Vrignaud
Marielle Chiron-Blondel
Marie-Christine Bissery
Eric Furfine
Jocelyn Holash
Jesse M Cedarbaum
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1824504(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PL1824504T3 publication Critical patent/PL1824504T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05824581T 2004-12-03 2005-12-02 Kombinacja przeciwnowotworowa zawierająca vegf-trap i 5fu lub jedną z jego pochodnych PL1824504T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
PCT/FR2005/003005 WO2006059012A1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives
EP05824581A EP1824504B1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant vegf-trap et du 5fu ou un de ses derives

Publications (1)

Publication Number Publication Date
PL1824504T3 true PL1824504T3 (pl) 2009-08-31

Family

ID=34954452

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05824581T PL1824504T3 (pl) 2004-12-03 2005-12-02 Kombinacja przeciwnowotworowa zawierająca vegf-trap i 5fu lub jedną z jego pochodnych

Country Status (25)

Country Link
US (3) US20060178305A1 (OSRAM)
EP (1) EP1824504B1 (OSRAM)
JP (1) JP4980236B2 (OSRAM)
KR (1) KR101313404B1 (OSRAM)
CN (1) CN101068564B (OSRAM)
AT (1) ATE426409T1 (OSRAM)
AU (1) AU2005311191C1 (OSRAM)
BR (1) BRPI0518700B8 (OSRAM)
CA (1) CA2586735C (OSRAM)
CY (3) CY1109181T1 (OSRAM)
DE (1) DE602005013568D1 (OSRAM)
DK (1) DK1824504T3 (OSRAM)
ES (1) ES2324233T3 (OSRAM)
FR (3) FR2878749B1 (OSRAM)
HR (1) HRP20090336T1 (OSRAM)
IL (1) IL183481A (OSRAM)
LU (2) LU92202I2 (OSRAM)
ME (1) ME01706B (OSRAM)
MX (1) MX2007006607A (OSRAM)
PL (1) PL1824504T3 (OSRAM)
PT (1) PT1824504E (OSRAM)
RS (1) RS50769B (OSRAM)
RU (1) RU2384344C2 (OSRAM)
SI (1) SI1824504T1 (OSRAM)
WO (1) WO2006059012A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
HU230159B1 (hu) * 1999-06-08 2015-09-28 Regeneron Pharmaceuticals, Inc. VEGF receptor kimérák alkalmazása vaszkuláris permeabilitással jellemzett szembetegség kezelésére
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Also Published As

Publication number Publication date
CA2586735C (fr) 2014-08-12
JP2008521866A (ja) 2008-06-26
FR2878749B1 (fr) 2007-12-21
CN101068564B (zh) 2010-12-15
BRPI0518700B1 (pt) 2020-02-11
BRPI0518700A2 (pt) 2008-12-02
KR20070091130A (ko) 2007-09-07
CY1109181T1 (el) 2014-07-02
FR2878749A1 (fr) 2006-06-09
RU2384344C2 (ru) 2010-03-20
LU92202I9 (OSRAM) 2019-01-15
CY2013018I1 (el) 2020-05-29
US8388963B2 (en) 2013-03-05
EP1824504A1 (fr) 2007-08-29
US20060178305A1 (en) 2006-08-10
IL183481A0 (en) 2007-09-20
LU92203I2 (fr) 2013-11-15
US20130184205A1 (en) 2013-07-18
US20090285841A1 (en) 2009-11-19
HRP20090336T1 (hr) 2009-07-31
CN101068564A (zh) 2007-11-07
LU92202I2 (fr) 2013-11-15
RS50769B (sr) 2010-08-31
WO2006059012A1 (fr) 2006-06-08
AU2005311191C1 (en) 2015-04-30
FR13C0024I1 (fr) 2013-05-24
PT1824504E (pt) 2009-06-25
RU2007123607A (ru) 2009-01-10
AU2005311191A1 (en) 2006-06-08
CA2586735A1 (fr) 2006-06-08
JP4980236B2 (ja) 2012-07-18
ME01706B (me) 2010-08-31
ES2324233T3 (es) 2009-08-03
DE602005013568D1 (de) 2009-05-07
KR101313404B1 (ko) 2013-10-01
ATE426409T1 (de) 2009-04-15
IL183481A (en) 2013-09-30
DK1824504T3 (da) 2009-07-20
MX2007006607A (es) 2007-07-25
HK1114769A1 (en) 2008-11-14
CY2013017I1 (el) 2014-07-02
FR13C0025I1 (fr) 2013-05-24
AU2005311191B2 (en) 2011-12-08
BRPI0518700B8 (pt) 2021-05-25
SI1824504T1 (sl) 2009-08-31
LU92203I9 (OSRAM) 2019-01-15
EP1824504B1 (fr) 2009-03-25

Similar Documents

Publication Publication Date Title
LU92202I9 (OSRAM)
GEP20125691B (en) Compounds and compositions as protein kinase inhibitors
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
PL2530083T3 (pl) Inhibitory kinazy tyrozynowej brutona
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
DOP2002000438A (es) Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
GB0226434D0 (en) Combination product
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
EA200970353A1 (ru) Комбинированное лекарственное средство
SE0300457D0 (sv) Novel compounds
EA200971103A1 (ru) Иммуноцитокины для лечения рака в сочетании с химиотерапевтическими агентами
TW200716561A (en) P38 inhibitors and methods of use thereof
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
BRPI0419229A (pt) derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
WO2007012967A3 (en) Combination of voriconazole and fluconazole
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors